- Home
- ZLAB vs TGNA Comparison
ZLAB vs TGNA Comparison
Compare ZLAB & TGNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- TGNA
- Stock Information
- Founded
- ZLAB 2013
- TGNA 1906
- Country
- ZLAB China
- TGNA United States
- Employees
- ZLAB N/A
- TGNA N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- TGNA Broadcasting
- Sector
- ZLAB Health Care
- TGNA Industrials
- Exchange
- ZLAB Nasdaq
- TGNA Nasdaq
- Market Cap
- ZLAB 3.4B
- TGNA 2.9B
- IPO Year
- ZLAB 2017
- TGNA N/A
- Fundamental
- Price
- ZLAB $33.78
- TGNA $17.84
- Analyst Decision
- ZLAB Strong Buy
- TGNA Strong Buy
- Analyst Count
- ZLAB 3
- TGNA 4
- Target Price
- ZLAB $55.00
- TGNA $21.75
- AVG Volume (30 Days)
- ZLAB 752.8K
- TGNA 993.2K
- Earning Date
- ZLAB 02-27-2025
- TGNA 02-27-2025
- Dividend Yield
- ZLAB N/A
- TGNA 2.80%
- EPS Growth
- ZLAB N/A
- TGNA N/A
- EPS
- ZLAB N/A
- TGNA 2.81
- Revenue
- ZLAB $355,748,000.00
- TGNA $2,957,296,000.00
- Revenue This Year
- ZLAB $49.04
- TGNA $8.69
- Revenue Next Year
- ZLAB $46.80
- TGNA N/A
- P/E Ratio
- ZLAB N/A
- TGNA $6.35
- Revenue Growth
- ZLAB 35.01
- TGNA N/A
- 52 Week Low
- ZLAB $13.48
- TGNA $12.35
- 52 Week High
- ZLAB $36.60
- TGNA $19.62
- Technical
- Relative Strength Index (RSI)
- ZLAB 79.95
- TGNA 41.43
- Support Level
- ZLAB $30.61
- TGNA $17.81
- Resistance Level
- ZLAB $33.00
- TGNA $18.38
- Average True Range (ATR)
- ZLAB 1.32
- TGNA 0.35
- MACD
- ZLAB 0.58
- TGNA -0.03
- Stochastic Oscillator
- ZLAB 86.34
- TGNA 12.90
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About TGNA TEGNA Inc
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.